

For Immediate Release Q4 Net Profit up 81% to Rs 225 cr

Vadodara April 23rd, 2020

Alembic Pharmaceuticals Limited reported its consolidated unaudited financial results for the fourth quarter and year ending 31st March 2020.

Financial Highlights for the quarter

- Net Sales for the quarter up 30% to Rs 1207 crores
- Net Profit for the quarter up 81% to Rs 225 crores

Financial Highlights for the Year

- Net sales for the year up 17% to Rs 4606 crores.
- Net Profit for the year up 42% to Rs 829 crores.

Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said

"It was a remarkable year for the company where we recorded our highest revenue and profit ever. This was led by strong growth in the US generics business. During the fourth quarter we saw our India and ROW business also getting back to a robust growth."

Operational Highlights

International Business

- International Formulations grew 80% to Rs 710 crores in the quarter.
- International Formulations grew 39% to Rs 2473 crores for FY 20.
- US Generics grew 84% to Rs 577 crores for the quarter.
- US Generics grew 53% to Rs. 1976 crores for FY20.
- 10 ANDA filings during the quarter and 25 ANDA filings for FY20.
- Cumulative ANDA filings at 183.
- FY20 R&D spend at Rs 645 Crores, 14% of Sales.





India Formulations Business

- India formulations business grew by 13% for the quarter to Rs 342 crores as against Rs 302 crores last year.
- India formulations business for the year grew 3% to Rs 1425 crores.

Dividend

 The Board in its meeting held on 6th March, 2020 declared Interim Dividend on equity shares at Rs. 10.00 per share i.e. 500% for FY20 (P.Y. Rs. 5.50 per share i.e. 275%).

Summary of Total Revenue is as under:

(Rs in Crores)

Particulars	Q4 FY20	Q4 FY19	% Change	FY20	FY19	% Change
Formulation	IS EPAIR AR HARMAN MARKANASA		BRITISH AGENTALIAN ARRAMANIAN ARRAMANIAN		KARGERINGENBER MARKESE	eine laer jug onigen in sakk sakte
USA	577	313	84%	1976	1289	53%
ROW	132	81	63%	497	494	1%
India	342	302	13%	1425	1382	3%
API	155	230	-33%	708	770	-8%
Total	1207	927	30%	4606	3935	17%





The Profit break-up is as under:

(Rs in Crores)

Particulars	Q4 FY20	Q4 FY19	% Change	FY20	FY19	% Change
EBITDA	339	174	95%	1,213	875	39%
EBITDA %	28%	19%		26%	22%	
Profit Before Exceptional Items	298	139	114%	1,072	741	45%
Net Profit after Tax	225	124	81%	829	584	42%

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients.

Information about the company can be found at www.alembicpharmaceuticals.com (reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

Mitanshu Shah

For more information contact:

Aiay Kumar Desai

7.4.7	I I I I I I I I I I I I I I I I I I I	
Phone: +91 22 – 306 11681	Phone: +91 265 - 3007630	

Email: <u>ajay.desai@alembic.co.in</u> Email: <u>mitanshu.shah@alembic.co.in</u>

